Table 3

Adverse events and grade

EventToripalimab plus IMRT
N=25
All gradesGrade 1–2Grade 3Grade 4Grade 5
Acute toxicityNumber of patients with event (%)
 Thrombocytopenia1 (4.0)1 (4.0)0 (0.0)0 (0.0)0 (0.0)
 Neutropenia2 (8.0)2 (8.0)0 (0.0)0 (0.0)0 (0.0)
 Leukopenia4 (16.0)4 (16.0)0 (0.0)0 (0.0)0 (0.0)
 ALT elevation5 (20.0)5 (20.0)0 (0.0)0 (0.0)0 (0.0)
 AST elevation3 (12.0)3 (12.0)0 (0.0)0 (0.0)0 (0.0)
 Total bilirubin elevation0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)
 Direct bilirubin elevation0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)
 Blood cholesterol elevation6 (24.0)6 (24.0)0 (0.0)0 (0.0)0 (0.0)
 Blood triglyceride elevation12 (48.0)11 (44.0)1 (4.0)0 (0.0)0 (0.0)
 Hyperglycemia9 (36.0)9 (36.0)0 (0.0)0 (0.0)0 (0.0)
 Serum creatinine elevation13 (52.0)13 (52.0)0 (0.0)0 (0.0)0 (0.0)
 Creatine kinase elevation5 (20.0)4 (16.0)0 (0.0)1 (4.0)0 (0.0)
 Hypertension3 (12.0)3 (12.0)0 (0.0)0 (0.0)0 (0.0)
 Hypothyroidism8 (32.0)8 (32.0)0 (0.0)0 (0.0)0 (0.0
 Hyperthyroidism1 (4.0)1 (4.0)0 (0.0)0 (0.0)0 (0.0)
 Nausea19 (76.0)19 (76.0)0 (0.0)0 (0.0)0 (0.0)
 Vomiting2 (8.0)2 (8.0)0 (0.0)0 (0.0)0 (0.0)
 Diarrhea1 (4.0)1 (4.0)0 (0.0)0 (0.0)0 (0.0)
 Pruritus8 (32.0)8 (32.0)0 (0.0)0 (0.0)0 (0.0)
 Capillary hyperplasia1 (4.0)1 (4.0)0 (0.0)0 (0.0)0 (0.0)
 Fever1 (4.0)1 (4.0)0 (0.0)0 (0.0)0 (0.0)
 Weight loss11 (44.0)11 (44.0)0 (0.0)0 (0.0)0 (0.0)
 Fatigue22 (88.0)22 (88.0)0 (0.0)0 (0.0)0 (0.0)
 Myositis or myalgia4 (16.0)4 (16.0)0 (0.0)0 (0.0)0 (0.0)
 Joint pain0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)
 Pneumonia0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)
 Infusion reaction0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)
 Skin reaction10 (40.0)8 (32.0)2 (8.0)0 (0.0)0 (0.0)
 Mucositis23 (92.0)22 (88.0)1 (4.0)0 (0.0)0 (0.0)
 Dry mouth24 (96.0)24 (96.0)0 (0.0)0 (0.0)0 (0.0)
Late toxicity
 Nasopharyngeal wall necrosis11 (44.0)4 (16.0)3 (12.0)4 (16.0)0 (0.0)
 Massive nasal bleeding3 (12.0)0 (0.0)0 (0.0)2 (8.0)1 (4.0)
 Eye damage9 (36.0)9 (36.0)0 (0.0)0 (0.0)0 (0.0)
 Deafness18 (72.0)18 (72.0)0 (0.0)0 (0.0)0 (0.0)
 Trismus10 (40.0)9 (36.0)1 (4.0)0 (0.0)0 (0.0)
 Dry mouth18 (72.0)18 (72.0)0 (0.0)0 (0.0)0 (0.0)
 Skin reaction4 (16.0)4 (16.0)0 (0.0)0 (0.0)0 (0.0)
 Neck tissue damage7 (28.0)7 (28.0)0 (0.0)0 (0.0)0 (0.0)
 Cranial neuropathy9 (36.0)9 (36.0)0 (0.0)0 (0.0)0 (0.0)

  • All data are presented as No. (%).

  • ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; IMRT, intensity-modulated radiotherapy .